Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Isradipine is a dihydropyridine calcium channel blocker used for the treatment of hypertension. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class.
- Mechanism
- Curator reviewed
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, isradipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives isradipine additional arterial selectivity. At therapeutic sub-toxic concentrations, isradipine has little effect on cardiac myocytes and conduction cells.
- Primary indication
- For the management of mild to moderate essential hypertension.Curator reviewed · 1 structured indication
- Formula / weight
- C19H21N3O5 · 371.3871 g/mol (avg)
- First approval
- United States, 1998
Resolves to
HMJIYCCIJYRONP-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Isradipine, and which of those have an active Phase 3 trial?